Hormonal treatment of acne vulgaris: an update

Elsaie, Mohamed L.

doi:10.2147/ccid.s114830

Cited by 86 publications

(135 citation statements)

References 47 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Androgens and their receptors are the primary targets of systemic hormonal therapies for the treatment of acne, particularly in females . Androgens regulate production of sebum and acne formation in both sexes . Most are produced by the adrenal glands and gonads and some are produced at the sebaceous gland level as well.…”

Section: Treatment Of Acnementioning

confidence: 99%

“…Most candidates for hormonal therapy are women with signs of hyperandrogenism who respond poorly to topical therapy for their acne, flares of facial acne prior to menstruation, and deep nodules of the neck and face . The goals of hormonal therapy are to suppress production of androgens in adrenal glands, ovaries, and the pituitary gland, and to block androgen nuclear receptors on target cells, keratinocytes, and sebocytes . Hormones therapy may be used in combination with antibiotics, BPO, azelaic acid, and retinoids.…”

Section: Treatment Of Acnementioning

confidence: 99%

“…A nonsteroidal androgen receptor blocker, flutamide is contraindicated in pregnancy but is effective against acne, hirsuitism, and androgenic alopecia. Cyproterone acetate, an anti‐androgen and a progestin, may be used alone or in combination with ethinyl estradiol to treat acne . Cyproterone acetate shows high improvement in acne when used alone …”

Section: Treatment Of Acnementioning

confidence: 99%

“…Cyproterone acetate, an anti‐androgen and a progestin, may be used alone or in combination with ethinyl estradiol to treat acne . Cyproterone acetate shows high improvement in acne when used alone …”

Section: Treatment Of Acnementioning

confidence: 99%

“…41 Androgens regulate production of sebum and acne formation in both sexes. 42,43 Most are produced by the adrenal glands and gonads and some are produced at the sebaceous gland level as well.…”

Section: Isotretinoinmentioning

confidence: 99%

See 4 more Smart Citations

Current treatments of acne: Medications, lights, lasers, and a novel 650‐μs 1064‐nm Nd: YAG laser

Gold

Goldberg

Nestor

2017

J of Cosmetic Dermatology

View full text Add to dashboard Cite

The treatment of acne, especially severe acne, remains a challenge to dermatologists. Therapies include retinoids, antibiotics, hormones, lights, lasers, and various combinations of these modalities. Acne is currently considered a chronic rather than an adolescent condition. The appropriate treatment depends on the patient and the severity of disease. The purpose of this study was to review current therapies for acne of all severities and to introduce the 650-μs 1064-nm laser for the treatment of acne.

show abstract

Section: Treatment Of Acnementioning

confidence: 99%

Section: Treatment Of Acnementioning

confidence: 99%

Section: Treatment Of Acnementioning

confidence: 99%

Section: Treatment Of Acnementioning

confidence: 99%

Section: Isotretinoinmentioning

confidence: 99%

See 3 more Smart Citations

Current treatments of acne: Medications, lights, lasers, and a novel 650‐μs 1064‐nm Nd: YAG laser

Gold

Goldberg

Nestor

2017

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Acne is a common, multifactorial skin condition, and treatments with novel mechanisms have been elusive. OBJECTIVE To assess the safety and efficacy of clascoterone cream, 1%, a novel topical androgen receptor inhibitor, in 2 phase 3 randomized clinical trials (CB-03-01/25 and CB-03-01/26). DESIGN, SETTING, AND PARTICIPANTS Two identical, multicenter, randomized, vehicle-controlled, double-blind, phase 3 studies conducted from November 2015 to April 2018 evaluated the efficacy and safety of use of clascoterone cream, 1%, in males and nonpregnant females 9 years and older with moderate or severe facial acne as scored on the Investigator's Global Assessment scale. Participants were enrolled if they had 30 to 75 inflammatory lesions and 30 to 100 noninflammatory lesions. INTERVENTIONS Patients were randomized to treatment with clascoterone cream, 1%, or vehicle cream and applied approximately 1 g to the whole face twice daily for 12 weeks. MAIN OUTCOMES AND MEASURES Treatment success was defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear), and a 2-grade or greater improvement from baseline and absolute change from baseline in noninflammatory and inflammatory lesion counts at week 12. Safety measures included adverse event frequency and severity. RESULTS A total of 1440 patients were randomzied in 2 studies. In CB-03-01/25, 353 participants were randomized to treatment with clascoterone cream, 1% (median [range] age, 18.0 [10-58] years; 221 [62.6%] female), and 355 participants were randomized to treatment with vehicle cream (median [range] age, 18.0 [9-50] years; 215 (60.6%) female); in CB-03-01/26, 369 participants were randomized to treatment with clascoterone cream, 1% (median [range] age, 18.0 [10-50] years; 243 [65.9%] female), and 363 participants were randomized to treatment with vehicle cream (median [range] age, 18.0 [range, 11-42] years; 221 [60.9%] female). At week 12, treatment success rates in CB-03-01/25 and CB-03-01/26 with clascoterone cream, 1%, were 18.4% (point estimate, 2.3; 95% CI, 1.4-3.8; P < .001) and 20.3% (point estimate, 3.7; 95% CI, 2.2-6.3; P < .001) vs 9.0% and 6.5% with vehicle, respectively. At week 12, in both CB-03-01/25 and CB-03-01/26, treatment with clascoterone cream, 1%, resulted in a significant reduction in absolute noninflammatory lesions from baseline to −19.4 (point estimate difference, −6.4; 95% CI, −10.3 to −2.6; P < .001) and −19.4 (point estimate difference, −8.6; 95% CI, −12.3 to −4.9; P < .001) vs −13.0 and −10.8 with vehicle, respectively, as well as a reduction in inflammatory lesions from baseline to −19.3 (point estimate difference, −3.8; 95% CI, −6.4 to −1.3; P < .001) and −20.0 (point estimate difference, −7.4; 95% CI, −9.8 to −5.1; P < .001) vs −15.5 and −12.6 with vehicle, respectively. Adverse events rates were low and mostly mild; the predominant local skin reaction was trace or mild erythema. CONCLUSIONS AND RELEVANCE Use of clascoterone cream, 1%, for acne treatment appears to demonstrate favorable efficacy and...

show abstract

Acne

Layton,

Zouboulis,

Whitehouse

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Acne (also known as acne vulgaris) is one of the most common inflammatory dermatoses seen globally. It can result in significant and indelible scarring and pigment change as well as profound psychosocial issues as a result of clinically active acne and resulting sequelae. This chapter covers the numerous clinical presentations and associations of acne and considers optimum management regimes for all.

show abstract

Hormonal treatment of acne vulgaris: an update

Cited by 86 publications

References 47 publications

Current treatments of acne: Medications, lights, lasers, and a novel 650‐μs 1064‐nm Nd: YAG laser

Current treatments of acne: Medications, lights, lasers, and a novel 650‐μs 1064‐nm Nd: YAG laser

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne

Acne

Contact Info

Product

Resources

About